addS

Showing posts with label Diabetes. Show all posts
Showing posts with label Diabetes. Show all posts

Monday 21 October 2013

Type 2 Diabetes Market A Shifting Treatment Algorithm and Intensified Competition Expected to Drive to 2019: Market Report



Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

GBI Research has released its latest report for the pharmaceuticals industry, “Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019”. There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.


Scope

  • A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
  • In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
  • Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
  • Discussion of the drivers and barriers for market growth

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175605

Reasons to Buy

  • Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
  • Understand the strengths and weaknesses of each product
  • Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

Table of Contents

1 Table of Contents 1
1.1 List of Tables 5
1.2 List of Figures 6

2 Executive Summary 7
2.1 A Highly Competitive and Growing Market 7
2.2 Strong Pipeline Containing a Diverse Set of Products 8

3 Introduction 9
3.1 Epidemiology 9
3.2 Symptoms 9
3.3 Etiology 10
3.4 Pathophysiology 10
3.5 Co-morbidities and Complications 11
3.6 Classification 12
3.7 Prognosis 13
3.8 Diagnosis 13
3.9 Assessing Treatment Effectiveness 15
3.10 Treatment Algorithm 15
3.10.1 The Role of Insulin in Type 2 Diabetes 17
3.10.2 Non-insulin Diabetic Drugs 18
3.10.3 Other Drugs 20
3.11 GBI Research Report Guidance 20

4 Key Marketed Products 21
4.1 DPP-4 Inhibitors 21
4.1.1 Januvia (sitagliptin) – Merck & Co 21
4.1.2 Tradjenta (linagliptin) – Boehringer Ingelheim 23
4.1.3 Onglyza (saxagliptin) – Bristol-Myers Squibb and AstraZeneca 24
4.1.4 Nesina (alogliptin) – Takeda 24
4.1.5 Galvus (vildagliptin) – Novartis 25
4.2 GLP-1 Agonists 26
4.2.1 Byetta and Bydureon (exenatide) – Bristol-Myers Squibb 26
4.2.2 Lyxumia (lixisenatide) – Sanofi 27
4.2.3 Victoza (liraglutide) – Novo Nordisk 28
4.3 Sulfonylureas 28
4.3.1 Glimepiride 28
4.3.2 Gliclazide 29
4.4 Thiazolidinediones 30
4.4.1 Actos (pioglitazone) – Takeda Pharmaceuticals Limited 30
4.4.2 Avandia (rosiglitazone) – GlaxoSmithKline 31
4.5 Other 32
4.5.1 Metformin 32
4.5.2 Lantus (insulin glargine) – Sanofi 33
4.5.3 Levemir (insulin detemir) – Novo Nordisk 34
4.5.4 Forxiga (dapagliflozin) – Bristol-Myers Squibb 35
4.6 Heat Map for Marketed Products 35

To buy the copy of this report, visit:  http://www.marketresearchreports.biz/analysis/175605

5 Pipeline for Type 2 Diabetes 39
5.1 Overall Pipeline 39
5.2 Therapeutic Classes 40
5.3 Rate of Attrition 42
5.3.1 Failure Rate by Molecule Type 42
5.3.2 Failure Rate by Therapeutic Class 44
5.4 Reasons for Failure of Developmental Programs 46
5.5 Clinical Trial Duration 46
5.5.1 Duration by Molecule Type 46
5.5.2 Duration by Therapeutic Class 47
5.6 Clinical Trial Size 48
5.6.1 Clinical Trial Size by Molecule Type 49
5.6.2 Clinical Trial Size by Therapeutic Class 51
5.7 Promising Drugs in the Pipeline 53
5.7.1 LY-2189265 (dulaglutide) – Eli Lilly 53
5.7.2 Albiglutide – GlaxoSmithKline 53
5.7.3 LC15-044 (gemigliptin) – LG Life Sciences 54
5.7.4 TAK-875 – Takeda 54
5.7.5 Ipragliflozin – Astellas Pharma 55
5.7.6 LX-4211 – Lexicon Pharmaceuticals 55
5.7.7 Imeglimin – Poxel SA 56
5.7.8 CCX-140-B – ChemoCentryx 56
5.7.9 Semaglutide – Novo Nordisk A/S 57
5.7.10 PC-DAC Exendin-4 – ConjuChem Biotechnologies 57
5.8 Heat Map for Pipeline Products 57
5.9 Conclusion 60


Latest Reports:

Global and China Terephthaloyl chloride (TPC) Industry 2013 Market Research Report: http://www.marketresearchreports.biz/analysis-details/global-and-china-terephthaloyl-chloride-tpc-industry-2013-market-research-report      
The report firstly introduced Terephthaloyl chloride(TPC) basic information included definition classification application industry chain structure industry overview; international market analysis, Global and China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Terephthaloyl chloride(TPC) Industry policy and plan, Terephthaloyl chloride(TPC) product specification, manufacturing process, product cost structure etc. then statistics Global and China key manufacturers Terephthaloyl chloride(TPC) capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Terephthaloyl chloride(TPC) products customers application capacity market position information etc company related information, then collect all these manufacturers data and listed Global and China Terephthaloyl chloride(TPC) capacity production capacity market share production market share supply demand shortage import export consumption etc data statistics, and then introduced Global and China Terephthaloyl chloride(TPC) 2009-2014 capacity production price cost profit production value gross margin etc information. 

Click Here To Download Detail Report:  http://www.marketresearchreports.biz/sample/sample/175833

And also listed Terephthaloyl chloride(TPC) upstream raw materials equipments and down stream client survey analysis and Terephthaloyl chloride(TPC) marketing channels industry development trend and proposals. In the end, this report introduced Terephthaloyl chloride(TPC) new project SWOT analysis Investment feasibility analysis investment return analysis and related research conclusions and development trend analysis of Global and China Terephthaloyl chloride(TPC) industry. 

In a word, it was a depth research report on Global and China Terephthaloyl chloride(TPC) Industry. And thanks to the support and assistance from Terephthaloyl chloride(TPC) Industry chain related technical experts and marketing engineers during Research Team survey and interviews.


Global and China m-Phthalodinitrile Industry 2013 Market Research Report: http://www.marketresearchreports.biz/analysis-details/global-and-china-m-phthalodinitrile-industry-2013-market-research-report       

The report firstly introduced m-Phthalodinitrile basic information included definition classification application industry chain structure industry overview; international market analysis, Global and China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, m-Phthalodinitrile Industry policy and plan, m-Phthalodinitrile product specification, manufacturing process, product cost structure etc. then statistics Global and China key manufacturers m-Phthalodinitrile capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers m-Phthalodinitrile products customers application capacity market position information etc company related information, then collect all these manufacturers data and listed Global and China m-Phthalodinitrile capacity production capacity market share production market share supply demand shortage import export consumption etc data statistics, and then introduced Global and China m-Phthalodinitrile 2009-2014 capacity production price cost profit production value gross margin etc information. 

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/177051

And also listed m-Phthalodinitrile upstream raw materials equipments and down stream client survey analysis and m-Phthalodinitrile marketing channels industry development trend and proposals. In the end, this report introduced m-Phthalodinitrile new project SWOT analysis Investment feasibility analysis investment return analysis and related research conclusions and development trend analysis of Global and China m-Phthalodinitrile industry. 

In a word, it was a depth research report on Global and China m-Phthalodinitrile Industry. And thanks to the support and assistance from m-Phthalodinitrile Industry chain related technical experts and marketing engineers during Research Team survey and interviews.

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Blog: http://mrrfocuseconomics.blogspot.com/

Wednesday 25 September 2013

Research and Markets: A Shifting Treatment Algorithm and Intensified Competition Expected Type 2 Diabetes Market Growth by 2019

Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

GBI Research has released its latest report for the pharmaceuticals industry, “Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019”. There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones. 


Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

Scope

  • A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis
  • In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.
  • Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain
  • Discussion of the drivers and barriers for market growth

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/175605

Reasons to Buy

  • Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm
  • Understand the strengths and weaknesses of each product
  • Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent
  • Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

 About Us
Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
With a team of experienced consultants we are committed to serve our clients in a way which increase their efficiency, reduce costs and saves time. Our professional search engine helps you in finding the best and latest market research report with just one click of the mouse. Our database represents the most updates and latest market research report collections form all the leading market research publishers across the globe

Contact

M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948